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Background: Changes over time in the callus during intermittent administration of parathyroid hormone (PTH)
were studied in rabbit distraction osteogenesis models.
Method: Models of distraction osteogenesis in Japanese white rabbits were created, and distraction osteogenesis
(total length: 10.5 mm) was performed for 2 weeks. Simultaneously with the start of distraction, 30 rabbits received
4 weeks of subcutaneous administration of 30 μg/kg of PTH(1–34), teriparatide, (P-group: n = 15) or saline (N-group:
n = 15) every other day. The tibias of five rabbits were dissected at 6, 8, and 10 weeks after surgery to perform
bone mineral density (BMD), peripheral quantitative computed tomography (pQCT), and mechanical testing.
Results: The mean BMD had no significant differences over time at 6, 8, and 10 weeks after surgery between the
P-group and the N-group. On pQCT, the P-group had significant increases in total bone cross-sectional area of the
callus compared to the N-group at 8 and 10 weeks after surgery. On mechanical testing, the P-group’s absorption
energy had not changed at 6 weeks after surgery compared to the N-group, but it had significantly increased at
8 weeks. At 10 weeks after surgery, the N-group’s absorption energy rapidly increased, and the difference between
the two groups disappeared.
Conclusion: The intermittent administration of PTH(1–34), teriparatide, for 4 weeks every other day from the start
of distraction had the potential to shorten the callus maturation period in the rabbit distraction osteogenesis
models.
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Distraction osteogenesis has broad-reaching clinical
applications in the lengthening of short body height
caused by bone diseases [1] and of limbs shortened by
various conditions, including comminuted fractures of
the long bone shafts, pyogenic osteomyelitis, bone de-
fects after bone tumor resection, and pseudoarthrosis
[2]. One of its advantages is that bone grafting is not
required even with large bone defects. Conversely, one
of the greatest disadvantages clinically is the long period
of fitting an external fixation device. This is associated
with an increased risk of infection at pin insertion sites
for the external fixation device, as well as increased* Correspondence: ohh.tetsu@hotmail.co.jp
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creativecommons.org/publicdomain/zero/1.0/economic and mental burdens on patients because of
longer hospitalization.
In order to shorten the treatment period, there are
ongoing attempts to combine distraction osteogenesis
with other treatment modalities, such as ultrasound [3],
extracorporeal shock waves [4], alternating-current elec-
trical stimulation [5], dynamization [6], and administra-
tion of various bone metabolism-adjusting drugs and
cytokines [7–9]. Bone metabolism-adjusting drugs that
could be a candidate for the combination therapy with
distraction osteogenesis include bisphosphonates (BPH),
which are bone resorption inhibitors, and bone anabolic
agents. The former increase bone strength, but the callus
that is formed remains without being remodeled, and
the mechanical properties of the callus are believed to
be inferior to the callus of the normal healing processticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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is a bone anabolic agent, has had clinical applications in
the treatment of osteoporosis, and it has been reported
to have significant effects in increasing bone mineral
density (BMD) and inhibiting fractures [13]; recently,
similar effects were obtained even with intermittent
administration given once a week [14]. Experimental
studies with distraction osteogenesis models have been
reported, and an effect of PTH on callus formation has
also been demonstrated in rabbit distraction osteogen-
esis models [15, 16]. However, no report has examined
the detailed changes over time regarding how long the
callus-promoting effects of PTH continue.
In this study, changes over time in callus formation were
studied during intermittent administration of PTH(1–34),
teriparatide, in rabbit distraction osteogenesis models.
Materials and methods
PTH preparation
The PTH in this study used is human PTH(1–34), teri-
paratide acetate (Asahi Kasei Pharma, Tokyo, Japan),
which is a sequence of 34 amino acids from the N-
terminus. The molecular weight of teriparatide is 4418
Da. A solution of 10 μg/mL of PTH was created using
saline as the solvent and then stored frozen at −80 °C in
portions of 1-mL containers. The solution was thawed at
room temperature immediately prior to administration;
the amount of solution corresponding to the weight of
each individual rabbit was calculated, and the necessary
amount was used for experiments. The same amount of
saline was used as a control.
Animals and test groups
Thirty Japanese white rabbits, weighing 2.2–2.6 kg, were
divided into two groups (15 rabbits per group), a 30-μg/kg
PTH administration group (P-group), and a saline ad-
ministration group (N-group) as a control.
The distraction osteogenesis model
The distraction osteogenesis model was based on Maru-
no’s method [15]. Anesthesia consisted of intramuscular
injection of 15 mg/kg of ketamine hydrochloride (Sankyo
Seiyaku, Tokyo, Japan), followed by intravenous adminis-
tration of 30 mg/kg of pentobarbital (Tanabe Seiyaku,
Tokyo, Japan). An incision of about 40 mm was made to
the medial side of the right hind lower leg, and the peri-
osteum of the medial surface of the tibia was exposed.
Without peeling back of the periosteum, two half-pins of
2.0 mm in diameter were punctured so as to straddle the
tibiofibular junction with a middle distance of 20 mm
between the two pins, and then an external fixator for
human short tubular bone (OrthofixM-100; Verona,
Italy) was fitted. A drill hole osteotomy was performed at
the middle between the two pins, a 10-mm distal site ofthe tibiofibular junction. During osteotomy, saline was
dropping at the osteotomy site to prevent heating. The
osteotomy stumps were connected by turning the ex-
tender in the shortening direction to make no gap, and
then the skin was sutured (Fig. 1). The left hind leg was
left untreated. The hind legs were loaded from immedi-
ately after surgery, and no limitations were applied to
movement. According to the method of Little et al. [10],
a 7-day wait after surgery was followed by 14 consecutive
days of bone distraction every 12 h, 0.375 mm each time
(Fig. 2). The amount of bone distraction was 0.75 mm
per day, with a total distraction distance of 10.5 mm,
corresponding to about 9.4 % of the total length of the
tibia. Simultaneously with the start of distraction, 30 μg/
kg of PTH (P-group) or saline (N-group) was adminis-
tered by subcutaneous injection once every other day for
4 weeks. After the 2 weeks of distraction, rabbits were
sacrificed after a 3-, 5-, or 7-week bone-hardening period,
at 6, 8, or 10 weeks after surgery, respectively. Then, all
rabbits (five rabbits each for two groups at three inter-
vals) were euthanized, and their tibias were dissected
after removing the external fixation device. The dissected
tibias were wrapped in gauze soaked with saline and
stored frozen at −80 °C until testing.
Measurements
Dissected tibias were naturally thawed at room tem-
perature and subjected to various imaging examinations,
and then a three-point bending test was performed.
A. Bone mineral content (BMC) and bone mineral
density (BMD)
BMC and BMD of the distraction osteogenesis callus
were measured using dual-energy X-ray absorptiometry
(DXA) for small animals by the DCS-600EX-R (Aloka,
Japan). BMD was measured in 4 mm width up and down
from the middle of the distraction osteogenesis callus.
B. Peripheral quantitative computed tomography (pQCT)
A BMD device for small animals, the XCT Research
SA+pQCT (Stratec Medizintechnik Gmbh, Pforzheim,
Germany), was used to assess the cross-sectional shapes
of the distraction osteogenesis callus. Measurements
were taken at three sites (the center of the distraction
osteogenesis callus and two midpoints between the
center and the osteotomy site). Each parameter was
measured with a CT width of 0.46 mm, using 690 mg/cm3
as a threshold value of typical cortical bone. Measurement
parameters were as follows: a) Total-Area (mm3); total
cross-sectional area of the callus, b) Cortical-Area (mm3);
cross-sectional area of the cortical bone, measured with a
threshold value 690 mg/cm3 for typical cortical bone and
a threshold value 267 mg/cm3 for immature bone cortex,
c) Medial-Area (mm3); medullary cavity area, which was
found by subtracting the cortical bone from the total area,
and d) Cortical-Peri (mm); the perimeter of the cortical
Fig. 1 Schematic representation of the callus distraction model. The Orthofix M-100 was fixed to the tibia with four half pins of 2.0 mm. The
middle two pins were set at 20 mm apart, and at the center of these, a drill hole osteotomy was performed using a 1.0-mm drill. In order to fit
the fragments, an extender is turned in the shortening direction, and the bone fragments were brought into contact with each other
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the cortical bone endosteum, and f) Cortical-Thk (mm);
the cortical bone thickness.
C. Mechanical testing (three-point bending test)
A three-point bending test was measured using the
GRAPH-2000E (Shimadzu, Japan). The anterior surface
of the tibia was faced upward, and the posterior surface
was faced downward so that the center of the osteogen-
esis callus was located at the middle between support
points at 20-mm distance. Then, pressure was applied
with a crosshead speed by 2 mm/s at the center of the
callus from the anterior tibia surface). The measurementFig. 2 Experimental protocol. The latency period was 1 week, followed by
intermittent PTH 30 μg or vehicle was infused locally for 4 weeks from the
after operationparameters were a) absorption energy until callus frac-
ture (work to failure) (N.mm), b) peak force to make
callus fracture (peak load) (N), and c) the slope of the
linear portion of the load-deformation curve (stiffness)
(MPa). The measurement of one of five rabbits in the
control group sacrificed at 10 weeks after surgery had
failed, and the data was omitted from analysis.
Statistical analysis
For statistical testing, the IBM SPSS statistics software
was used, and significance was set at p < 0.05. Numerical
values were represented by means ± standard deviation.2 weeks of lengthening and 7 weeks of consolidation time. Either
start of lengthening. The animals were sacrificed at 6, 8, and 10 weeks
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This study conformed with Japan’s “Law concerning the
protection and control of animals,” “Standard concern-
ing the breeding and protection of laboratory animals,”
“Laboratory Animal Guidelines of Kyorin University,”
and other relevant guidelines, and it was conducted in a
laboratory of Kyorin University’s Department of Ortho-
pedic Surgery.Results
Bone mineral content (BMC) and bone mineral density
(BMD)
As shown in Table 1, the mean BMC tended to be
higher in the P-group than in the N-group at 6 weeks
after surgery, but there were no significant differences
between the two groups all through the study period.
There were also no significant changes over time in each
group. As for the mean BMD, the P-group tended to
have higher values at all times, but there were no signi-
ficant differences between the groups. There were no
significant changes over time in each group.Peripheral quantitative computed tomography (pQCT)
a. Total cross-sectional area of the callus (Total-Area)
As shown in Table 2, the Total-Area tended to be
greater in the P-group than in the N-group at all times,
and the difference was significant at 8 and 10 weeks after
surgery (p < 0.05). There were no significant changes
over time in the Total-Area in each group.
b. Cortical bone cross-sectional area (Cortical-Area)
In the mean Cortical-Area with a threshold value of
690 mg/cm3, there were no significant differences be-
tween the two groups. In both groups, the mean value
reached a maximum at 8 weeks after surgery, but the
changes were not significant over time in each group.
On the other hand, the mean Cortical-Area with a thresh-
old value of 267 mg/cm3 decreased over time in both
groups. The area tended to be greater in the P-group at
all times, but there were no significant differences except
at 6 weeks after surgery (p < 0.05).
c. Medullary cavity area (Medial-Area)
The mean Medial-Area was greater in the P-group
than in the N-group at all times, with the differences
being significant at 8 and 10 weeks after surgery (p < 0.05).Table 1 Bone mineral content and bone mineral density
6 weeks 8
Control PTH30 P-values C
n 5 5 5
Bone mineral content (mg) 276 ± 61 475 ± 60 ns 2
Bone mineral density (mg/cm2) 309 ± 8 379 ± 71 ns 3d. Perimeter of the cortical bone periosteum (Cortical-
Peri), perimeter of the cortical bone endosteum (Cor-
tical-Endo), and cortical bone thickness (Cortical-Thk)
As for the mean Cortical-Peri, the perimeter tended to
be greater in the P-group than in the N-group over time,
but there were no significant differences. There were no
significant changes over time in each group. In the mean
Cortical-Endo, the perimeter tended to be greater in the
P-group than in the N-group over time, and there were
significant differences at 8 and 10 weeks after surgery
(p < 0.05). There was no change over time in the N-
group, but the perimeter in the P-group tended to be
greater at 8 and 10 weeks than 6 weeks after surgery. In
the mean Cortical-Thk, there were no significant differ-
ences over time between the two groups. The thickness
became greater until 8 weeks and then decreased at 10
weeks in both groups, but these changes were not
significant.Mechanical testing (three-point bending test)
a. Absorption energy until callus fracture (work to
failure)
As shown in Table 3, the mean value of work to
failure increased significantly in the N-group at 10
weeks after surgery (p < 0.05) compared to 6 and 8
weeks. In the P-group, it increased significantly at 8
weeks and substantially reached a plateau at 10 weeks
after surgery. The energy tended to increase more rap-
idly in the P-group than in the N-group at 6 weeks,
and it reached to be significant at 8 weeks after sur-
gery. At 10 weeks, however, the N-group also rapidly
increased, and there was no longer a significant differ-
ence between the two groups (Fig. 3).
b. Peak force to make callus fracture (peak load)
There were no significant differences between the two
groups over time. And there were no significant changes
over time in each group.
c. Slope of the linear portion of the load-deformation
curve (Stiffness)
Stiffness tended to increase at 6 and 8 weeks after
surgery in the N-group, while in the P-group, stiffness
showed the greatest value at 6 weeks after surgery and
gradually decreased at 8 and 10 weeks after surgery.
There were no significant differences over time in the
two groups.weeks 10 weeks
ontrol PTH30 P-values Control PTH30 P-values
5 5 5
42 ± 58 290 ± 71 ns 305 ± 43 299 ± 66 ns
21 ± 56 354 ± 41 ns 253 ± 8 272 ± 37 ns
Table 2 Measurements with peripheral quantitative computed tomography (pQCT)
6 weeks 8 weeks 10 weeks
Control PTH30 P-values Control PTH30 P-values Control PTH30 P-values
n 5 5 5 5 5 5
Total-Area (mm3) 63 ± 8 70 ± 14 ns 64 ± 22 83 ± 13 P < 0.05 65 ± 12 82 ± 26 P < 0.05
Cortical-Area: 690 mg/cm3 (mm3) 19 ± 4 22 ± 11 ns 25 ± 7 25 ± 8 ns 21 ± 3 21 ± 5 ns
Cortical-Area: 267 mg/cm3 (mm3) 60 ± 7 68 ± 10 P < 0.05 50 ± 14 54 ± 19 ns 35 ± 7 40 ± 6 ns
Medial-Area (mm3) 43 ± 7 50.7 ± 11 ns 29 ± 5 55 ± 8 P < 0.05 39 ± 7 54 ± 18 P < 0.05
Cortical-Peri (mm) 28 ± 2 30 ± 3 ns 28 ± 5 32 ± 2 ns 28 ± 3 32 ± 5 ns
Cortical-Endo (mm) 23 ± 3 24 ± 3 ns 21 ± 7 29 ± 2 P < 0.05 23 ± 4 27 ± 5 P < 0.05
Cortical-Thk (mm) 0.7 ± 0.02 0.8 ± 0.4 ns 1.1 ± 0.4 0.9 ± 0.3 ns 0.9 ± 0.2 0.7 ± 0.2 ns
Total-Area total cross-sectional area of the callus, Cortical-Area cortical bone cross-sectional area (690 mg/cm3: typical cortical bone, 267 mg/cm3: including
immature bone cortex), Medial-Area medullary cavity area, Cortical-Peri perimeter of the cortical bone periosteum, Cortical-Endo perimeter of the cortical bone
endosteum, Cortical-Thk cortical bone thickness
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The greatest advantage of distraction osteogenesis for
shorter limbs is that it does not need a donor bone such
as vascularized bone grafts. However, distraction osteo-
genesis requires a bone-hardening period for maturation
of the callus, and it usually requires two to three times
longer than the distraction period. Shortening the callus
maturation period is one of the greatest problems,
which should be resolved in distraction osteogenesis,
but there has been no useful combination therapy in
clinical practice.
PTH is a polypeptide hormone composed of 84 amino
acid residues, but its biological activity resides in 1–34 of
the N-terminus region. This human PTH(1–34), teripara-
tide, is known to promote both bone formation and bone
resorption when administered intermittently in rats. Since
the increase in bone formation is greater than that in bone
resorption, bone mass increases as a result [17].
Effects of intermittent PTH(1–34) administration on
cancellous bone are thought to involve improving the
bone microarchitecture and enhancing bone strength,
such as by increasing the connectivity of the trabecula
and cancellous bone mass, and shifting the trabecular
structure from rod-like to plate-like structure [18]. As aTable 3 Structural properties by three-point bending analysis
6 weeks 8 weeks
Control PTH30 P-values Control
n 5 5 5
Work to failure (N.mm) 224 ± 35 370 ± 243 ns 170 ± 7
Peak load (N) 326 ± 40 474 ± 177 ns 304 ± 7
Stiffness (MPa) 337 ± 90 454 ± 225 ns 454 ± 3
Work to failure absorption energy until callus fracture, peak load peak force to make
curve
aThe data from one of five rabbits were omitted due to experimental failure
bP < 0.05, compared to 6 weeks in PTH30 group
cP < 0.05, compared to 6 and 8 weeks in control groupresult, the lumbar spine BMD increases and new verte-
bral fractures are diminished clinically [13]. For cortical
bone, PTH(1–34) has been thought to promote the cor-
tical porosity and reduce the cortical bone width and
cortical bone strength. However, the cortical bone width
in the ilium did increase significantly, and there was no
significant change in porosity [18–20]. In the study using
monkey tibias and femurs, bone strength was increased
by greater thickness of the cortical bone [21]. PTH(1–
34) also increased cortical thickness and cortical porosity
in tibia and radius clinically, however, bone strength was
not deteriorated and similar as zoledronic acid treatment
[22]. Recently, treatment of PTH(1–34) for 2 years has
shown to reduce non-vertebral fragile fracture [23].
There have also been numerous reports on basic re-
search for fracture healing with intermittent PTH admin-
istration. In rat femur fracture models, PTH increased
the BMC, the ultimate load, the callus mass, the callus
area, and callus strength [24–29]. And PTH had an effect
in promoting temporal and volume-dependent cortical
ossification at fracture sites [24]. PTH is thought to
promote fracture healing. Furthermore, expansion of
the periosteal diameter increases cortical bone strength,
and this phenomenon is called cortical drift, and PTH10 weeks
PTH30 P-values Control PTH30 P-values
5 4a 5
7 583 ± 86b P < 0.05 587 ± 241c 639 ± 105b ns
2 436 ± 156 ns 443 ± 204 339 ± 50 ns
9 427 ± 72 ns 389 ± 66 338 ± 148 ns
callus fracture, stiffness the slope of the linear portion of the load-deformation
Fig. 3 Absorption energy until callus fracture (Work to failure). The
mean work to failure increases significantly in the PTH30 μg group
compared with the control group at 8 weeks after operation. The
change has almost disappeared at 10 weeks after operation
Fig. 4 Cortical drift. Intermittently administering PTH affected the
periosteal and endocortical membrane, with the callus expanding
outward, and the overall volume becoming greater
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were caused by the periosteal and endocortical membrane
reactions [21].
On the other hand, there were few reports about the
effects of intermittently administering PTH(1–34) on
bone distraction osteogenesis [15, 16, 30–32]. Seebach
et al. used rat femur distraction models by administering
PTH daily, and with a 20-day bone-hardening period,
the callus volume and BMD increased 58 and 24 %,
respectively, and the stiffness and ultimate load increased
50 %. With the 40-day bone-hardening period, bone mass
also increased similarly, but they reported that the 20-day
bone-hardening period showed a greater effect [30]. How-
ever, cortical bone remodeling in rats, which are a species
of rodent and therefore have no Haversian system, is be-
lieved to be higher response to PTH than in humans.
Aleksyniene et al. [16, 32] used a distraction osteogenesis
model with rabbit tibias, an animal with the same remod-
eling as humans. There was an increase in BMD and bone
strength in a group of daily PTH administration for a
10-day distraction period followed by a 20-day bone-
hardening period. And a group of daily PTH administra-
tion for only a 20-day bone-hardening period showed the
same results as the former group. Maruno et al. [15] per-
formed intermittent administration of 10 or 30 μg/kg of
PTH every other day in rabbit distraction osteogenesis
models. They administered PTH for 4 weeks after the
start of a 14-day distraction with a 5-week bone-
hardening period. They reported that the PTH 30 μg/kg
group had increased cortical bone formation and callus
width, and the callus strength was significantly greater
than PTH 10 μg/kg and control groups. However, the dur-
ation of this positive effect by PTH was unknown. In the
present study, PTH was administered every other day, and
the bone-hardening period was changed to 1.5-fold (6weeks after surgery), 2.5-fold (8 weeks after surgery), or
3.5-fold (10 weeks after surgery) after a 14-day distraction
in order to investigate the changes in the course of dis-
traction callus formation.
BMD did not change over time in this study. Bone
strength, however, did increase significantly in the P-
group at 8 weeks after surgery compared to the N-group,
and there was no longer a difference at 10 weeks. This
result seemed to mean that PTH’s effect of enhancing
bone strength occurred in a bone-hardening period that
was 3–5 weeks after distraction (8–10 weeks after surgery)
in this model. Considering this results in pQCT, the mean
total cross-sectional area of the distraction callus had no
significant change over time in each group, but the P-
group values were greater than the N-group values at all
times, and the P-group had a significantly greater cross-
sectional area at 8 and 10 weeks after surgery. For mean
cortical bone cross-sectional area with a threshold value
of 267 mg/cm3, which included immature bone, the P-
group increased significantly compared to the N-group at
6 weeks after surgery, and the values also tended to be
greater at a threshold value of 690 mg/cm3 for typical
bone cortex, suggesting that the effects of administering
PTH were already observed at 6 weeks after surgery. For
medullary cavity area, the fact that the P-group had
significantly increased compared to the N-group at 8 and
10 weeks after surgery implied that PTH accelerated the
resorption of the immature bone inside the medullary
cavity and promoted the remodeling of the distraction
callus. This results resembled the appearance of cortical
drift as in normal bone changes, and the distraction callus
extended outward and the overall bone volume was
increased (Fig. 4).
In terms of the changes over time in callus formation by
intermittently administering PTH in the present study, an
acceleration of remodeling had already appeared for the
Ohata et al. Journal of Orthopaedic Surgery and Research  (2015) 10:88 Page 7 of 821-day bone-hardening period after distraction (at 6 weeks
after surgery). An increase in the periosteal diameter asso-
ciated with enhancing of the periosteal ossification of the
cortical bone for a 35-day bone-hardening period (at 8
weeks) was observed, and bone strength was accelerated
as a result of enhanced bone remodeling. For 49 days of
the bone-hardening period (at 10 weeks), the bone
strength of the N-group was rapidly caught up to that of
the PTH group, and there was no difference between the
two groups. Intermittently administering PTH has the
potential to accelerate the bone remodeling and reduce
the callus maturation period in distraction osteogenesis.
Conclusions
Intermittently administering PTH for 4 weeks from the
start of distraction in rabbit distraction osteogenesis
models accelerated remodeling of the callus from the early
stage of from 21 to 49 days after distraction compared to
the control group and reduced the callus maturation
period by about 2 weeks, therefore demonstrating its use-
fulness for distraction osteogenesis.
Abbreviations
PTH: parathyroid hormone; BMD: bone mineral density; pQCT: peripheral
quantitative computed tomography.
Competing interests
Author, the corresponding author, and all of co-authors declare that no
benefits in any form have been received or will be received from a
commercial party related directly or indirectly to the subject of this article.
Authors’ contributions
TO and HM carried out operation. SI conceived of the study design. TO, HM,
and SI interpreted the data and drafted the manuscript. TO and SI involved
in revising the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
This work was supported by the Department of Orthopaedic Surgery, Kyorin
University School of Medicine. Human PTH(1–34), teriparatide acetate, was
offered without charge by Asahi Kasei Pharma Company, Tokyo, Japan.
Received: 9 January 2015 Accepted: 20 May 2015
References
1. Yasui N, Kawabata H, Kojimoto H. Lengthening of lower limbs in patients
with achondroplasia. Clin Orthop. 1997;344:298–306.
2. Tsuchiya H, Tomita K, Minematsu K. Limb salvage using distraction
osteogenesis; a classification of the technique. J Bone Joint Surg.
1997;79-B:403–11.
3. Shimazaki A, Inui K, Azuma Y. Low-intensity pulsed ultrasound accelerates
bone maturation in distraction osteogenesis in rabbits. J Bone Joint Surg.
2000;82-B:1077–82.
4. Shizuto M, Hiroyuki S, Kazuto N. The effect of low energy extracorporeal
shock wave on the callus formation during bone lengthening. J Jpn Assoc
External Fixation Limb Lengthening. 2003;14:119–22.
5. Kouei K, Yuichi T, Motoo H. The effect of alternating current electrical
stimulation to the lengthened callus in a experimental callotasis model.
Orthop Surg Traumatol. 2002;45:315–9.
6. Kassis B, Glorin C, Tabib W. Callus response to micromovement after
elongation in the rabbit. J Pediatr Orthop. 1996;16:480–3.
7. Okazaki H, Kurokawa T, Nakamura K. Stimulation of bone formation by
recombinant fibroblast growth factor-2 in callotasis bone lengthening of
rabbits. Calcif Tissue Int. 1999;64:542–6.8. Schumacher B, Albrechtsen J, Keller J. Periosteal insulin–like rowth factor I
and bone formation. Acta Orthop Scand. 1996;67:237–41.
9. Tsubota S, Tsuchiya H, Shinokawa Y. Transplantation of osteoblast-like cells
to the distracted callus in rabbits. J Bone Joint Surg. 1999;81-B:125–9.
10. Little DG, Cornell MS, Hile MS. Effect of pamidronate on distraction
osteogenesis and fixator-related osteoporosis. Injury. 2001;32:14–20.
11. Mashiba T, Turner CH, Hirano T. The effects of suppressed bone turnover by
bisphoshonates increases microdamage accumulation and reduces some
biomechanical properties in dog rib. J Bone Miner Res. 2000;15:613–20.
12. Mashiba T, Turner CH, Hirano T. The effects of suppressed bone turnover by
bisphoshonates on microdamage accumulation and biomechanical
properties in clinically relevant skeletal sites of beagles. Bone. 2001;28:524–31.
13. Neer RM, Arnaud CD, Zanchetta JR. Effect of parathyroid hormone (1–34) on
fracture and bone mineral density in postmenopausal women with
osteoporosis. N Eng J Med. 2001;344:1434–41.
14. Takami M, Kiyoshi N, Hiroshi N. Effect and safety of intermittent
weekly administration of human parathyroid hormone 1–34 in
patients with primary osteoporosis evaluated by histomorphometry
and microstructural analysis of iliac trabecular bone before and after
1 year of treatment. J Bone Miner Metab. 2004;22:569–76.
15. Maruno H. Effects of intermittent administration of parathyroid hormone on
distraction osteogenesis in rabbits. J Kyorin Med Soc. 2011;42:29–38.
16. Aleksyniene R, Thomsen JS, Eckardt H. Three-dimensional
microstructural properties of regenerated mineralizing tissue after PTH
(1–34) treatment in a rabbit tibial lengthening model. J Musculoskelet
Neuronal Interact. 2009;9:268–77.
17. Hock JM, Gera I. Effect of continuous and intermittent administration and
inhibition of resorption on the anabolic response of bone to parathyroid
hormone. J Bone Miner Res. 1992;7:65–72.
18. Jiang Y, Zhao J, Mitlak B. Recombinant human parathyroid hormone (1–34)
[teriparatide] improves both cortical and cancellous bone structure. J Bone
Miner Res. 2003;18:1932–41.
19. Dempster DW, Cosman F, Kurland ES. Effects of daily treatment with
parathyroid hormone on bone microarchitecture and turnover in patients
with osteoporosis: a paired biopsy study. J Bone Miner Res. 2001;16:1846–53.
20. Hodsman AB, Kisiel M, Adachi JD. Histomorphometric evidence for
increased bone turnover without change in cortical thickness or porosity
after 2 years of cyclical hPTH (1–34) therapy in women with severe
osteoporosis. Bone. 2000;27:311–8.
21. Manabe T, Mori S, Mashiba T. Human parathyroid hormone (1–34)
accelerates natural fracture healing process in the femoral osteotomy
model of cynomolgus monkeys. Bone. 2007;40:1475–82.
22. Hansen S, Hauge EM, Beck Jensen JE. Differing effects of p TH1–34,
p TH1–84, and zoledronic acid on bone microarchitecture and estimated
strength in postmenopausal women with osteoporosis: an 18-month open-
labeled observational study using HR-pQCT. J Bone Miner Res. 2013;28:736–45.
23. Silverman S, Miller P, Sebba A. The direct assessment of nonvertebral
fractures in community experience (DANCE) study: 2-year nonvertebral
fragility fracture results. Osteoporos Int. 2013;24:2309–17.
24. Alkhiary YM, Gerstenfeld LC, Krall E. Enhancement of experimental
fracture-healing by systemic administration of recombinant human
parathyroid
hormone (PTH 1–34). J Bone Joint Surg. 2005;87:731–41.
25. Holzer G, Majeska RJ, Lundy MW. Parathyroid hormone enhances fracture
healing. Clin Orthop Relat Res. 1999;366:258–63.
26. Toru H, Burr DB, Turner CH. Anabolic effects of human biosynthetic
parathyroid hormone fragment (1–34), LY333334, on remodeling and
mechanical properties of cortical bone in rabbits. J Bone Miner Res.
1999;14:536–45.
27. Andreassen TT, Ejersted C, Oxlund H. Intermittent parathyroid hormone
(1–34) treatment increases callus formation and mechanical strength of
healing rat fractures. J Bone Miner Res. 1999;14:960–8.
28. Andreassen TT, Flederius C, Ejersted C. Increases in callus formation and
mechanical strength of fracture healing in old rats treated with parathyroid
hormone. Acta Orthop Scand. 2001;72:304–7.
29. Nakajima A, Shimoji N, Shiomi K. Mechanism for the enhancement of
fracture healing in rats treated with intermittent low-dose human
parathyroid hormone (1–34). J Bone Miner Res. 2002;17:2038–47.
30. Seebach C, Skripitz R, Andreassen TT. Intermittent parathyroid hormone
(1–34) enhances mechanical strength and density of new bone after
distraction osteogenesis in rats. J Orthop Res. 2004;22:472–8.
Ohata et al. Journal of Orthopaedic Surgery and Research  (2015) 10:88 Page 8 of 831. Aleksyniene R, Eckardt H, Bundgaard K. Effects of parathyroid hormone on
newly regenerated bone during distraction osteogenesis in a rabbit tibial
lengthening model. A pilot study. Medicina. 2006;42:38–48.
32. Aleksyniene R, Thomsen JS, Eckardt H. Parathyroid hormone PTH (1–34)
increases the volume, mineral content, and mechanical properties of
regenerated mineralizing tissue after distraction osteogenesis in rabbits.
Acta Orthop. 2009;80:716–23.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
